UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1321-5
Program Prior Authorization/Notification
Medication Tabrecta® (capmatinib)
P&T Approval Date 7/2020, 7/2021, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Tabrecta (capmatinib) is a kinase inhibitor indicated for the treatment of adult patients with
metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to
mesenchymal-epithelial transition (MET) exon 14 skipping.
The National Cancer Comprehensive Network (NCCN) guideline also recommends use of
Tabrecta as single-agent therapy for NSCLC with high-level MET amplification.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Tabrecta will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Non-Small Cell Lung Cancer (NSCLC)
1. Initial Authorization
a. Tabrecta will be approved based on all of the following criteria:
(1) Both of the following:
(a) Diagnosis of non-small cell lung cancer (NSCLC)
-AND-
(b) One of the following:
© 2024 UnitedHealthcare Services, Inc.
1
i. Presence of mesenchymal-epithelial transition (MET) exon 14 skipping
positive tumors
ii. High level MET amplification in lung cancer
Authorization will be issued for 12 months.
2. Reauthorization
a. Tabrecta will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Tabrecta
therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Tabrecta [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation,
March 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
www.nccn.org. Accessed June 4, 2024.
© 2024 UnitedHealthcare Services, Inc.
2
Program Prior Authorization/Notification – Tabrecta® (capmatinib)
Change Control
7/2020 New program.
7/2021 Updated coverage criteria for NSCLC according to NCCN guidelines.
7/2022 Annual review. Added state mandate with no other changes to criteria.
Updated references.
7/2023 Annual review. Updated background with FDA regular approval.
Updated references.
7/2024 Annual review. Updated references.
© 2024 UnitedHealthcare Services, Inc.
3